SERCA 2a gene therapy - Celladon Corporation

Drug Profile

SERCA 2a gene therapy - Celladon Corporation

Alternative Names: AAV1/SERCA2a; Congestive heart failure gene therapy; MYDICAR; rAAV1-SERCA2a; SERCA2a gene therapy

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celladon; Targeted Genetics
  • Developer Celladon; Theragene Pharmaceuticals
  • Class Gene therapies; Heart failure therapies
  • Mechanism of Action Adenosine triphosphatase stimulants; Gene transference; Sarcoplasmic reticulum calcium-transporting ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure
  • Preclinical Pulmonary arterial hypertension; Renal failure
  • Discontinued Urinary incontinence

Most Recent Events

  • 29 Jun 2017 Theragene Pharmaceuticals acquires Mydicar® (rAAV1-SERCA2a) from Eiger BioPharmaceuticals
  • 29 Jun 2017 Phase-II clinical trials in Heart failure in France, Sweden, United Kingdom, Hungary, Poland, Israel, Netherlands, Germany, Denmark, Belgium, USA (Intracoronary)
  • 29 Jun 2017 Preclinical trials in Pulmonary arterial hypertension in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top